Related Tags >> Gattex Nycomed sclerosis drug BioNanomatrix

NPS Pharmaceuticals News

Most Popular NPS Pharmaceuticals Story

GSK ends NPS's osteoporosis drug study

September 26, 2008 — 8:20am ET | By Maureen Martino

Bad news for NPS Pharmaceuticals: the company announced late Thursday that its partner GlaxoSmithKline would abandon a Phase II study of Ronacalaret, an osteoporosis drug. According to SEC filings Read more...

NPS Pharmaceuticals Press Releases

NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for GATTEX® (teduglutide) for the Treatment of Adult Short
NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for GATTEX® (teduglutide) for the Treatment of Adult
NPS Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism
Phase 3 GATTEX(R) (teduglutide) Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome
GATTEX(R) (teduglutide) Meets Primary Efficacy Endpoint in Phase 3 Pivotal Study in Patients with Adult Short Bowel Syndrome

Latest Headlines

NPS wraps another positive PhIII study as parathyroid drug impresses
November 7, 2011
NPS Pharma shares sink after cancers reported in patients on bowel drug
November 1, 2011
NPS soars on positive Ph3 data for orphan SBS drug
January 31, 2011
GSK ends NPS's osteoporosis drug study
September 26, 2008
C&L: Milano tapped to run ViroPharma
February 27, 2008
ALSO NOTED: Acorda shares bounce on new data; Endo CEO hits the exit door; BioSante in protocol deal; and much more...
January 29, 2008
ALSO NOTED: More takeover targets for Big Pharma; Byetta trial delivers positive data; and much more...
October 31, 2007
NPS pockets $30M, parts ways with AstraZeneca
October 9, 2007

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events